A link between enhanced production and eventually release of immuno-enhancing cytokines in the peripheral blood, particularly IL-2, but also IFN-γ, and GM-SCF, as detected in the present study after taxane treatment, as well as IL-12 and IL-15 in other studies after monoclonal antibody therapy (MoAb 17-1A) (Baxevanis et al, submitted) and the observed enhancement of lymphocyte ability to respond to autologous stimuli via proliferation (overall increase in AMLR by almost 200–250%) or to efficiently exert their tumouricidal action via lysis of tumour targets can be envisaged. This evidence concerns the gene IFNG and neoplasm.